References:
1. Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia-negative classical myeloproliferative
neoplasms: critical concepts and management recommendations from European LeukemiaNet.
Leukemia. 2018; 32: 1057-1069.
2. Alvarez-Larrán A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as
primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010;116:1205-
1210.
3. Godfrey AL, Campbell PJ, MacLean C, et al. Hydroxycarbamide Plus Aspirin Versus Aspirin Alone
in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. .J Clin
Oncol. 2018;36:3361-3369.
4. Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International
Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).
Blood. 2012;120:5128-5133.
5. Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. Practice-relevant revision of IPSET-thrombosis
based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer
Journal. 2015;5:e369.
6. Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential
thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123:1544-51.
7. Grinfeld J, Nangalia J, Baxter EJ, et al. Classification and Personalized Prognosis in
Myeloproliferative Neoplasms. New England Journal of Medicine. 2018; 379: 1416-1430.